Thema: Presse: PI3-Kinase Inhibitor Against Brain Cancer
Presse: PI3-Kinase Inhibitor Against Brain Cancer
Tom[a]
05.09.2003 00:33:23
ComChem Scientific Advisor Publishes First In Vivo Efficacy For PI3-Kinase Inhibitor Against Brain Cancer, Uncovers Major Cell Signal Intercept Switch
Results published in the July 1st, 2003 issue of Cancer Research also show evidence that PTEN controls p53 and blocks tumor-induced angiogenesis
Sept. 3, 2003
ComChem announced today that Cancer Research published the results of pre-clinical research performed in the lab of Dr. Donald L. Durden, MD, PhD, of the Indiana University School of Medicine (IUSM). The article describes the scientific and clinical rationale identifying PTEN and PI3-Kinase (PI3k) as a non-redundant intercept cell signaling switch for cell survival, cell proliferation, angiogenesis, and apoptosis. The published results support the concept that controlling PTEN and PI3k with targeted small molecule drugs could provide significant advantages over several of today´s therapies for cancer and multiple other disorders. The Cancer Research article presents the first pre-clinical evidence for the in vivo efficacy using a small molecule PI3k inhibitor in the treatment of malignant gliomas in several animal models. Furthermore, the research presented evidence that both PTEN and PI3k inhibitors regulate p53 function and display in vivo antiangiogenic and antitumor activity. The findings demonstrate that the balance between PTEN and PI3k serves as a non-redundant control switch. These results support the ComChem Interceptor product development activities aimed at producing drugs capable of selectively controlling this switch which is expected to represent a significant improvement in treating cancer.
New class of drugs, improving current therapies´ shortcomings - ComChem´s approach:
Many of the current therapies, including Genentech´s Avastin and ImClone´s Erbitux, have only been able to interfere with one of the many redundant, and often non-critical, cellular signals, and thus have only represented marginal improvements to current therapies. ComChem´s approach represents a new class of drugs aimed at dramatically improving theses current therapies by targeting the major non-redundant control point uncovered in Dr. Durden´s research.
"This research, combined with the research and collaboration of several of my cell signaling colleagues, has not only uncovered the control signaling mechanism integral for cell survival, but also validates that we can manage these specific signals with small molecule drugs," says Dr. Durden. "Our early drug candidates at ComChem are showing strong results, and I look forward to advancing our pre-clinical studies into human clinical trials."
Results published in the July 1st, 2003 issue of Cancer Research also show evidence that PTEN controls p53 and blocks tumor-induced angiogenesis
Sept. 3, 2003
ComChem announced today that Cancer Research published the results of pre-clinical research performed in the lab of Dr. Donald L. Durden, MD, PhD, of the Indiana University School of Medicine (IUSM). The article describes the scientific and clinical rationale identifying PTEN and PI3-Kinase (PI3k) as a non-redundant intercept cell signaling switch for cell survival, cell proliferation, angiogenesis, and apoptosis. The published results support the concept that controlling PTEN and PI3k with targeted small molecule drugs could provide significant advantages over several of today´s therapies for cancer and multiple other disorders. The Cancer Research article presents the first pre-clinical evidence for the in vivo efficacy using a small molecule PI3k inhibitor in the treatment of malignant gliomas in several animal models. Furthermore, the research presented evidence that both PTEN and PI3k inhibitors regulate p53 function and display in vivo antiangiogenic and antitumor activity. The findings demonstrate that the balance between PTEN and PI3k serves as a non-redundant control switch. These results support the ComChem Interceptor product development activities aimed at producing drugs capable of selectively controlling this switch which is expected to represent a significant improvement in treating cancer.
New class of drugs, improving current therapies´ shortcomings - ComChem´s approach:
Many of the current therapies, including Genentech´s Avastin and ImClone´s Erbitux, have only been able to interfere with one of the many redundant, and often non-critical, cellular signals, and thus have only represented marginal improvements to current therapies. ComChem´s approach represents a new class of drugs aimed at dramatically improving theses current therapies by targeting the major non-redundant control point uncovered in Dr. Durden´s research.
"This research, combined with the research and collaboration of several of my cell signaling colleagues, has not only uncovered the control signaling mechanism integral for cell survival, but also validates that we can manage these specific signals with small molecule drugs," says Dr. Durden. "Our early drug candidates at ComChem are showing strong results, and I look forward to advancing our pre-clinical studies into human clinical trials."
Tom[a]
